Infectious Disease Therapeutics
Market - Regional Analysis
On the basis of region, global Infectious
Disease Therapeutics Market is segmented into North America, Latin America,
Europe, Middle East, Asia Pacific, and Africa. North America holds dominant
position in infectious disease therapeutics market, followed by Europe. North
America drive the infectious disease therapeutics market, owing to increasing
research and development studies by various government and pharmaceutical
organizations about infectious diseases and its diagnosis. Furthermore, high
prevalence and awareness of infectious diseases among people, in turn opting for
early detection, is expected to drive growth of infectious disease therapeutics
market in this region. For instance, according to the Centers for Disease
Control and Prevention (CDC), the U.S. reported around 26,203 cases of Lyme
disease between 2006 and 2016. According to the same source, around 10,265
deaths were reported due to alcohol-impaired driving crashes in 2015, which
accounted for around 29% of all traffic-related deaths in the U.S.
Asia Pacific is expected to
witness fastest growth over the forecast period. Rising demand for efficient
and quick diagnostic testing, increasing number of strategies adopted by market
players to expand their geographical reach in this region, and engagement of
government organizations in minimizing the disease burden are factors that are
expected to drive market growth in Asia Pacific region. For instance, in March
2013, Qiagen N.V. launched its careHPV test in China. CareHPV is a molecular
diagnostic test designed to screen for high risk human papillomavirus (HPV) at
low-resource settings such as areas lacking electricity, water or laboratories.
Qiagen also gained the approval from China's State Food and Drug Administration
(SFDA) for the careHPV in 2012. Moreover, in March 2018, Government of India
launched the TB Free India Campaign with an aim to completely eliminate
tuberculosis (TB) by 2025.
Infectious disease is one of the
leading cause of significant burden in healthcare industry globally. These
disease can also be termed as transmissible disease or communicable disease is
caused by various infectious agents including virus, viroids, bacteria,
nematodes such as parasitic roundworms and pinworms, arthropods such as ticks,
mites, fleas, and lice, fungi such as ringworm, and other macroparasites such
as tapeworms and other helminths. Introduction of various technologically
advanced diagnosis and treatment option and improvements in hygiene,
vaccination, and antimicrobial therapy have decreased the number of deaths
caused from infectious diseases. However, emergence and re-emergence of
infectious diseases substantially affect the health outcomes of global
population.
* The sample copy includes: Report Summary, Table of
Contents, Segmentation, Competitive Landscape, Report Structure, Methodology.
Request a sample copy
of this report: https://www.coherentmarketinsights.com/insight/request-sample/1658
Global Infectious Disease
Therapeutics Market Drivers
Infectious disease therapeutics
market is expected to witness significant growth over the forecast period,
owing to increasing prevalence of infectious diseases, increasing awareness
regarding the early diagnosis of infectious diseases, and increasing research
funding activities by various private and government organizations. For
instance, according to the National Ambulatory Medical Care Survey: 2015 data
findings, 16.8 million visits to physician offices for infectious and parasitic
diseases were registered in the U.S. According to the same source, since
September 2012, it has been notified that around 2,143 laboratory-confirmed cases
of infection with MERS-CoV.
The World Health Organization
(WHO) also added that GISRS (Global Influenza Surveillance and Response System)
laboratories, from April 2, 2018 to April 15, 2018, tested over 137,071 specimens
from various National Influenza centers (NIC) and other national influenza
laboratories of 113 countries. Among these collected specimens, around 21,639
were positive for influenza viruses, wherein 12,034 (55.6%) were classified as
influenza A and 9,605 (44.4%) as influenza B. According to the Centers for
Disease Control and Prevention (CDC), around 5,251 deaths due to influenza
infection were registered in the U.S. in 2015. According to the World Health
Organization (WHO), in 2015, around 32,000 estimated deaths from tuberculosis
and around 3, 23,000 new cases of TB cases were registered in Europe. According
to the data published in European Centre for Disease Prevention and Control
(ECDC), in February 2018, around 44,000 people die annually from respiratory
diseases associated with seasonal influenza in Europe, out of a total of around
6,50,000 global deaths annually.
Moreover, increasing advancements
in rapid diagnosis of various infectious diseases allowing early and quicker
diagnosis is greatly impacting the medical outcome of disease treatment.
Advanced technologies such as lateral flow, agglutination assays, and solid
phase that are used in rapid diagnostics of infectious diseases are integrated
with innovative features such as portability of handheld devices, offering
point-of-care treatment to the patients. Moreover, advancements in the
technology of point-of care diagnostics is expected to drive growth of
infectious disease therapeutic market over the forecast period. For instance,
in 2014, Becton, Dickinson, and Company offered point-of-care system BD
FACSPresto for HIV/AIDS. It offers percentage results of CD4 T lymphocytes and
hemoglobin concentration. Moreover, in January 2017, Infectious Disease
Research Institute (IDRI) developed a fusion antigen, which is used as a part
of diagnostic test manufactured by InBios International, Inc. for Chagas
disease.
Browse Research
Report: https://www.coherentmarketinsights.com/ongoing-insight/infectious-disease-therapeutics-market-1658
Moreover, research funding is
provided by various government and private organizations for infectious
diseases to provide effective diagnostic and treatment options. For instance,
in November 2016, QuantuMDx Group received funding from Bill & Melinda
Gates Foundation to develop and test company’s CAPTURE-XT pathogen
concentration technology and Q-POC molecular diagnostic platform for rapid low
cost detection of tuberculosis. In January 2018, University of Glasgow-led
project received US$ 1.85 million funding, which is a part of Global Challenges
Research Fund (GCRF). This project will develop new tests for parasitic
diseases and rapid testing in remote locations to help enable rapid diagnosis
and rapid treatment of infectious diseases.
Global Infectious Disease
Therapeutics Market Restraint
Lack of awareness about
treatments for disorders, low adoption of treatments, and lack of reimbursement
for certain infectious diseases in selected countries are factors that are
expected to restrain growth of infectious disease therapeutics market over the
forecast period. Moreover, Africa and Asia have high incidence of infectious
disorders and low penetration rate of treatments for the same. For instance,
according to AVERT, a global HIV and AIDS charity organization based in U.K.,
in 2015, 6.5 million individuals were infected with Human Immunodeficiency
Virus (HIV) in the West and Central African region and around 28% of the HIV
infected people were accessing antiretroviral therapy. Furthermore, increasing
availability of counterfeit drugs in Asian countries is expected to pose
significant threat to the market during the forecast period.
Infectious Disease Therapeutics
Market – Competitive Landscape
Key players operating in the
infectious disease therapeutics market include Gilead Sciences, Inc.,
GlaxoSmithKline plc, Janssen Pharmaceutical, BioCryst Pharmaceuticals, Inc., F.
Hoffmann-La Roche AG, Boehringer Ingelheim GmbH, Merck & Co., Inc., and
Novartis International AG. Key players are developing new products for the
treatment of infectious diseases and are also receiving approvals to
commercialize their products. For instance, in May 2017, Merck received FDA
approval for its ISENTRESS HD, a new 1200 mg integrase inhibitor for HIV-1
infected patients. This drug can also be used in combination therapy with other
antiretroviral.
Buy-Now this research
report: https://www.coherentmarketinsights.com/insight/buy-now/1658
About
Coherent Market Insights:
Coherent
Market Insights is a prominent market research and consulting firm offering
action-ready syndicated research reports, custom market analysis, consulting
services, and competitive analysis through various recommendations related to
emerging market trends, technologies, and potential absolute dollar
opportunity.
Contact
Us:
mailto:sales@coherentmarketinsights.com
U.S.
Office:
Name: Mr. Shah
Coherent Market
Insights 1001 4th Ave,
# 3200
Seattle, WA 98154, U.S.
US : +1-206-701-6702
UK : +44-020-8133-4027
JAPAN
: +050-5539-1737
No comments:
Post a Comment